Cardona V, Ansotegui IJ, Ebisawa M, El-Gamal Y, Fernandez Rivas M, Fineman S, et al. World allergy organization anaphylaxis guidance 2020. World Allergy Organ J. 2020 Oct 1;13(10).
Food Allergy Canada and the Canadian Society of Allergy and Clinical Immunology. National Food Allergy Action Plan: Charting the Path Forward. 2019.
Gabrielli S, Clarke A, Morris J, et al. Evaluation of Prehospital Management in a Canadian Emergency Department Anaphylaxis Cohort. J Allergy Clin Immunol Pract. April 2019.
Worm M, Francuzik W, Renaudin J-M, et al. Factors increasing the risk for a severe reaction in anaphylaxis: An analysis of Data from The European Anaphylaxis Registry. Allergy. January 2018.
Church MK, Maurer M, Simons FER, et al. Risk of first-generation H1-antihistamines: A GA2LEN position paper. Allergy Eur J Allergy Clin Immunol. 2010;65(4):459-466.
Alqurashi W, Ellis AK. Do Corticosteroids Prevent Biphasic Anaphylaxis?. J Allergy Clin Immunol Pract. 2017;5(5):1194-1205.
Shaker MS, Wallace D V, Golden DBK, et al. Anaphylaxis: A 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. J Allergy Clin Immunol. 2020;145(4):1082-1123. doi:10.1016/j.jaci.2020.01.017
Alqurashi W, Awadia A, Pouliot A, et al. The Canadian anaphylaxis action plan for kids: development and validation. Patient Educ Couns. 2020;103(1):227-233.
Halbrich M, Mack DP, Carr S, Watson W, Kim H. CSACI position statement: epinephrine auto-injectors and children < 15 kg. Allergy Asthma Clin Immunol. 2015 Jun 12;11(1):20.

Pour la liste complète des données probantes qui ont informé l’élaboration des Recommandations de base sur Risque suicidaire : Dépistage & évaluation, voir le Référentiel médical.

Pour en savoir plus sur le processus de développement, voir notre site web.